Radiofrequency heat‑enhanced direct intratumoral chemotherapy for prostate cancer

Abstract

A novel, minimally invasive interventional technique, radiofrequency heat (RFH), has been suggested to improve the efficacy of chemotherapy for solid organ tumors. However, the treatment for prostate cancer has not been completely characterized. The aim of the present study was to investigate the in vitro and in vivo efficiency of chemotherapy in combination with RFH for the treatment of prostate cancer. The following four treatment groups were included: i) No treatment (control); ii) RFH-only; iii) chemotherapy (docetaxel)-only; and iv) combination therapy of docetaxel and RFH in human prostate cancer (HPC) cell lines and mice with HPC xenografts. In the in vitro experiments, a heating guidewire was attached under the bottom of the last chamber of the four-chamber cell culture slide, and was then connected to a radiofrequency (RF) generator. In the in vivo experiments, a tumor model was generated by subcutaneously injecting human prostate cancer cells into 24 male nu/nu mice. RFH was conducted by inserting the 0.022-inch heating-guidewire into the tumor. The follow-up magnetic resonance imaging demonstrated a significant reduction in the average tumor size in animals treated with combination therapy compared with those receiving RFH-only and chemotherapy-only. The number of apoptotic cells and the average apoptotic index of the combination therapy group were significantly higher compared with those of the other three treatment groups. In conclusion, the results of the present study suggested that RFH is able to increase the therapeutic efficiency of docetaxel in prostate cancer, and this study serves as a foundation for the future development of an interventional molecular image-guided local treatment strategy for prostate cancer that integrates RF technology, interventional oncology and direct intratumoral chemotherapy, as a replacement for systemic chemotherapy.

Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?

“…Most reported in vitro as well as all in vivo experimental studies simulated treatment with intravenous chemotherapy and local hyperthermia delivered to the area of the tumor by external devices, i.e. long drug exposure and hyperthermia during a short period during or after drug exposure to tumor cells, or used cells of tumors that do not cause peritoneal carcinomatosis (Tables I and II) (64)(65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78). Only in the report of Muller et al (22) and a previously published study of our center (79), were conditions encountered during HIPEC protocol mimicked, with high drug concentrations, hyperthermia for 30 to 120 minutes, and tumor cell types that do cause peritoneal carcinomatosis (i.e.…”

Astragaloside Ⅳ mediates the effect and mechanism of KPNB1 on biological behavior and tumor growth in prostate cancer

“…The prostate gland, the site of origin of prostate cancer, is located around the urethra and below the bladder and is an important male reproductive support organ whose main functions are urination and maintenance of sperm activity [ 4 ]. Currently, the main methods of treating prostate cancer include surgical resection [ 5 ], immunotherapy [ 6 ], chemotherapy [ 7 ], and androgen deprivation [ 8 ]. However, in its early phases of development, prostate cancer has not yet displayed any particular clinical symptoms [ 9 ].…”

Simulations of the Upper Critical Solution Temperature Behavior of Poly(ornithine-co-citrulline)s Using MARTINI-Based Coarse-Grained Force Fields

“…Drug delivery can thus be controlled by using nanoparticles responding to various stimuli such as light, magnetic field, ultrasound, or temperature. 1,2 Among these stimuli, hyperthermia is very promising since it can be easily locally induced using several techniques including ultrasound, 3 radiofrequency, 4 light, 5 or simply a water bath. The prerequisite for applying these techniques is to design thermoresponsive drug nanocarriers sensitive to mild hyperthermia (that is having a transition temperature in the 40-45 • C range).…”

“…The main strategy is to encapsulate drugs into stealth nanocarriers, which will distribute them through blood capillaries in the body, and then to locally apply a physical stimulus, which will specifically trigger the drug release in organs needing treatment only. Drug delivery can thus be controlled using nanoparticles responding to various stimuli such as light, magnetic field, ultrasound, or temperature. , Among these stimuli, hyperthermia is very promising since it can be easily locally induced using several techniques including ultrasound, radiofrequency, light, or simply a water bath. The prerequisite for applying these techniques is to design thermoresponsive drug nanocarriers sensitive to mild hyperthermia (i.e., having a transition temperature in the 40–45 °C range).…”